EFFECTS OF SIMVASTATIN ON CULTURED RAT RENAL INTERSTITIAL FIBROBLASTS

Nan CHEN,Ya LI,Weiming WANG,Haijin YU

DOI: https://doi.org/10.3969/j.issn.1006-298X.2000.05.003

2000-01-01

Abstract:OBJECTIVE Experimental and clinical studies have demonstrated beneficial effects of 3-hydromxy-3-methylgutaryl coen-zvme A reductase inhibitor on the structural and functional aspects of renal diseases. The present study is to investigate the effectsof Simvastatin on cultured interstitial fibroblasts from rat kidney(RFB), and the related mechanism. METHODOLOGY Inter-stitial fibroblasts were separated from the medulla of rat kidneys, and cultured and identified according to the reported methods. Ef-fects of Simvastatin on cell proliferation, cell-cycle and intracelluar signal transducfion of RFB in primary culture, were measured byMTT assay,flow cytometry and semi-quantity RT-PCR, respectively. β-actin was used as internal control. Subconfluent cells wereincubated 24 and 48 hours with various concentrations of Simvastatin(0.1 to 50 μmol/L), with or without 10% fetal bovine serum.RESULTS Renal interstitial fibroblasts showed positive-vimentin and positive-fibroblast surface antigen, but negative-cytokeratin.Simvastatin inhibited RFB proliferation in a dose-dependent manner, as compared to the controls( P < 0.05 ). The effect was moresignificant in the groups without fetal bovine serum. The treated groups had an increased percentage of cells in G0/G1 phase and areduced percentage of cells in S phase, PI values, DNA contents. But there was no significant difference between the treatmentgroups with respect to the percentage of cell in G2/M phase. Simvastatin suppressed the expression of c-fos mRNA in a dose-depen-dent manner as compared to the control group. CONCLUSION Simvastatin suppressed RFB proliferation by inhibiting DNAsynthesis and induceding cell-cycle arest at Gl phase. This effect on renal interstitial fibroblasts might be exerted, at least in part,via inhibition of the c-fos and c-jun-dependent mitogenic pathway. It implies that inhibitors of 3-hydroxy-3-methylgutaryl coenzymeA reductase have beneficial effect in progressive renal diseases.